8-K 1 a18938k.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1,2008 MILLENIA HOPE INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 98-0213828 (Commission file no.) (IRS Employer Identification No.) 490 du Parc Industriel suite 202 Longueuill, Quebec J9v 3V6 (Address of principal executive offices and zip code) Company's telephone number, including area code: (514) 664-4037 Item 1.01 Entry into a Definitive Material Agreement On August 1,2008 the Company sold 19% of its common shares in Millenia Hope Pharmaceuticals Inc., its former Canadian controlled subsidiary (also operating under the name Millenia Hope Biopharma), to Mr. Jacky Quan. In consideration of the aforementioned, Mr. Quan will invest $1.7 million Cdn in Millenia Hope Pharmaceuticals Inc., over a 1 year period commencing Aug 1,2008, to aid that company's cash flow needs. Mr. Quan also purchased, at the same time, 41% of that company's common shares from private interests, giving him a 60% ownership of that company's common shares and is currently operating this company under the name Bio-Quan Life Sciences. On the same date, Mr. Leonard Stella, that company's CEO, resigned his position as an Officer and as a Director and was replaced by Mr. Quan as the new CEO and a Director of Millenia Hope Pharmaceuticals Inc. On September 29,2008 Millenia Hope Pharmaceuticals Inc. made a request to stay all proceedings against it from its creditors, under the Canadian Bankruptcy and Insolvency Act with KPMG acting as the Trustee. As of now, no proposal in this matter has not been finalized by the relevant Canadian authorities. Item 5.02 Departure of Directors or Principal Officers; Election of Directions; Appointment of Principal Officers On January 5,2009 the Board of Directors of Millenia Hope accepted the December 16,2008 resignation of Mr. Joseph Daniele from his position as the Chief Legal Advisor and as a Director of the Company. His responsibilities at the Company are being handled by Mr. Leonard Stella, CEO, and Mr.Yehuda Kops, the COO. On January 5,2009 the Board of Directors of Millenia Hope welcomed back to the Company Dr. Soriba Cisse as their Chief Scientific Officer. Dr. Cisse was a former Officer of the Company and has now rejoined it his previous capacity. Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date January 9,2009 Millenia Hope Inc. By: /s/ Leonard Stella Name Leonard Stella Its: Chief Executive Officer By: /s/ Yehuda Kops Name: Yehuda Kops Its: Acting Chief Financial Officer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 18, 2005

MILLENIA HOPE INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

98-0213828

(Commission file no.) (IRS Employer Identification No.)

4055 St. Catherine St. West, Suite 151

Montreal, Quebec

H3Z 3J8

(Address of principal executive offices and zip code)

Company’s telephone number, including area code: (514) 846-5757

Item 1.01 Entry Into A Material Definitive Agreement.

On March 18, 2005, Millenia Hope, Inc. (the “Company”) entered into a Service Agreement with a biopharma corporation to render consulting services to enable Millenia Hope to file new patents and patent derivatives, for other indications, and new delivery methods for existing treatments. Compensation for the services, to be rendered over a 24 month period commencing March 18, 2005, is 7,300,000 common shares, valued as of the date of the Service Agreement at $1,460,000. The information set forth under Item 3.02 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 1.01.

Item 3.02 Unregistered Sales of Equity Securities.

Under the terms of the Service Agreement, the Company emitted 7,300,000 common shares, valued as of the date of the Service Agreement at $1,460,000, as payment for services to be rendered in the 24 month period commencing March 18, 2005.

Item 5.02 Departure of Directors or Principal Officers; Election of Directions; Appointment of Principal Officers

Mr. Raymond Roy, Executive Vice-President and Director of Millenia Hope, resigned on April 29, 2005 for personal reasons. The Board has not named any replacement for Mr. Roy, as of July 11, 2005.

Millenia Hope Inc., announced the resignation of its Vice-Chairman of the Board, Dr. Alexander Kavic, effective June 15, 2005. Dr. Kavic’s personal problems combined with his other employment duties did not allow him to properly fulfill his mandate as an officer and director of Millenia Hope. The Board of Directors, at a special meeting, asked for and accepted Dr. Kavic’s resignation. The Board has not named any replacement for Dr. Kavic, as of July 11, 2005.

On June 20, 2005, the Company issued a press release relating to the above matter.

Signatures:

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date July 11, 2005

Millenia Hope Inc.

By: /s/ Leonard Stella

Name: Leonard Stella

Its: Chief Executive Officer

By: /s/ Yehuda Kops

Name: Yehuda Kops

Its: Acting Chief Financial Officer

Changes in Certifying Accountant

Filing Compare · MILLENIA HOPE INC